镰状细胞病单倍体骨髓移植的国际学习协作2期试验
在一项国际多中心2期临床试验中,70例可评估的镰状细胞病患者接受含噻替哌和移植后环磷酰胺的非清髓性单倍体骨髓移植,2年无事件生存率为82.6%,2年总生存率为94.1%,移植失败仅见于18岁以下参与者。
要点
- 非清髓性单倍体骨髓移植后2年无事件生存率为82.6%,达到预设的至少80%的目标。
- 移植失败发生于8/70(11.4%),且仅见于年龄<18岁的参与者,均实现自体重建。
- 1年3-4级急性GVHD发生率为10%,2年中重度慢性GVHD发生率为10%。
核心结论
- 含噻替哌和移植后环磷酰胺的非清髓性单倍体骨髓移植是大多数成人(即使存在器官损害)可及的治疗选择,相比更昂贵的清髓性基因治疗和基因编辑具有优势;儿童需要额外策略以降低移植失败率。
研究设计与样本
- 国际多中心2期临床试验,在学习协作框架下开展,共70例可评估参与者,基于预处理方案评估。
- 试验注册号为NCT01850108。
主要发现
- 移植失败发生于8/70(11.4%),且仅见于年龄<18岁的参与者,均实现自体重建。
- 中位随访2.4年,2年Kaplan-Meier无事件生存概率为82.6%,2年总生存率为94.1%,儿童与成人参与者之间无差异。
- 排除8例移植失败者后,植入参与者在移植后第+180天和第+365天的中位全血供者嵌合率分别为100%(n=58),移植后1年96.6%(57/59)已停用免疫抑制。
- 1年3-4级急性移植物抗宿主病(GVHD)发生率为10%,2年中重度慢性GVHD发生率为10%。
- 5例参与者(7.1%)死于感染性并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative-related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier-based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate-severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.
引用
- Kassim AA, de la Fuente J, Nur E, et al. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease. Blood. 2024. PMID: 38493482. doi:10.1182/blood.2023023301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。